Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 166 AL 180

[Pharmacological properties of T-817MA, a novel neurotrophic agent, for treatment of Alzheimer's disease.]

Fukushima T.

Nihon Yakurigaku Zasshi. 2010 Jul;136(1):11-4. doi: 10.1254/fpj.136.11.

[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.]

Shitaka Y, Mitani Y, Nagakura A, Miyake A, Matsuoka N.

Nihon Yakurigaku Zasshi. 2010 Jul;136(1):15-20. doi: 10.1254/fpj.136.15.

[Current status of Alzheimer's disease immunotherapy and pharmacologic effect of BAN2401.]

Araki S.

Nihon Yakurigaku Zasshi. 2010 Jul;136(1):21-5. doi: 10.1254/fpj.136.21.

Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease

Re F, Airoldi C, Zona C, Masserini M, La Ferla B, Quattrocchi N, Nicotra F.

Curr Med Chem. 2010;17(27):2990-3006. doi: 10.2174/092986710791959729.

Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis

Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, Zhang R, Xu Y, Sun Y, Richardson S, Mackell J.

J Alzheimers Dis. 2010;21(3):843-51. doi: 10.3233/JAD-2010-100078.

Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats

Baraka A, ElGhotny S.

Eur J Pharmacol. 2010 Sep 1;641(2-3):123-7. doi: 10.1016/j.ejphar.2010.05.030. Epub 2010 Jun 8.

ADDLs and the signaling web that leads to Alzheimer's disease

Krafft GA, Klein WL.

Neuropharmacology. 2010 Sep-Oct;59(4-5):230-42. doi: 10.1016/j.neuropharm.2010.07.012. Epub 2010 Jul 23.

Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial

Iqbal K, Wang X, Blanchard J, Liu F, Gong CX, Grundke-Iqbal I.

Biochem Soc Trans. 2010 Aug;38(4):962-6. doi: 10.1042/BST0380962.

Inhibition of BACE1 for therapeutic use in Alzheimer's disease

Luo X, Yan R.

Int J Clin Exp Pathol. 2010 Jul 8;3(6):618-28.

[Development of new drugs for Alzheimer's disease]

Tabira T.

Brain Nerve. 2010 Jul;62(7):787-96.

Tau aggregation is a therapeutic target for Alzheimer's disease

Takashima A.

Curr Alzheimer Res. 2010 Dec;7(8):665-9. doi: 10.2174/156720510793611600.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A.

Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.

Cortical excitability in very mild Alzheimer's disease: a long-term follow-up study

Olazarán J, Prieto J, Cruz I, Esteban A.

J Neurol. 2010 Dec;257(12):2078-85. doi: 10.1007/s00415-010-5663-8. Epub 2010 Jul 31.

Statins for the treatment of dementia

McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007514. doi: 10.1002/14651858.CD007514.pub2.

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

Irwin N, Gault V, Flatt PR.

Expert Opin Investig Drugs. 2010 Sep;19(9):1039-48. doi: 10.1517/13543784.2010.513381.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias